Abstracts tagged "Biologic agents"

Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Lisa Baganz¹, Adrian Richter¹, Yvette Meißner², Matthias Schneider³, Anke Liebhaber⁴, Ilka Schwarze⁵, Anja Strangfeld⁶ and Angela Zink⁷, ¹German Rheumatism Research Center, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Rheumatologist, Halle, Germany, Halle, Germany, ⁵Rheumatologist, Leipzig, Germany, Leipzig, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…
Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Gareth T. Jones¹, Andrew Keat², Ejaz Pathan³ and Gary J. Macfarlane¹, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology., Northwick Park Hospital, London, United Kingdom, ³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
Abstract Number: 2447 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Sarah Dyball¹, Victoria Hoskins², Sharon Christy-Kilner² and Sahena Haque³, ¹Rheumatology, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ²University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology department, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for rheumatoid arthritis (RA) and costs less than Enbrel. This study aimed to evaluate the…
Abstract Number: 523 • 2017 ACR/ARHP Annual Meeting
Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan¹, Sau Mei Tse¹ and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence of occult hepatitis B carrier status and its associated factors in patients with rheumatic diseases undergoing biological therapies Methods: Consecutive…
Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting
Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies
Alain Saraux¹, René-Marc Flipo², Bernard Combe³, Jacques Tebib⁴, Christelle Baffie⁵, Isabelle Idier⁶ and Alain Cantagrel⁷, ¹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ²Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ³Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ⁴Rheumatology, University Hospital, Hospices civils de Lyon, Lyon, France, ⁵Statistics, Altizem on behalf of Roche, Boulogne Billancourt, France, ⁶Medical department, Chugai Pharma France, Paris La Defense, France, ⁷Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France
Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
Abstract Number: 1550 • 2017 ACR/ARHP Annual Meeting
One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry
Bente Glintborg¹, Emina Omerovic¹, Kamilla Danebod¹, Dorte Vendelbo Jensen¹, Henrik Nordin¹, Anne Gitte Loft¹, Stavros Chrysidis¹, Johnny Lillelund Raun¹, Oliver Hendricks¹, Hanne Lindegaard¹, Jakob Espesen¹, Susanne Jakobsen¹, Inger Marie J. Hansen¹, Jolanta Grydehøj¹, Emil Dalgaard¹, Dorte Dalsgaard Pedersen¹, Natalia Manilo², Lis Smedegaard Andersen³, Salome Kristensen¹, Asta Linauskas¹, Niels Steen Krogh⁴ and Merete Lund Hetland⁵, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, ³Department of Rheumatology, The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ⁴The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark
Background/Purpose: According to Danish national guidelines issued in April 2016, a non-medical switch from originator (ETA, Enbrel) to biosimilar Etanercept (SB4, Benepali) (50 mg s.c.)…
Abstract Number: 2464 • 2017 ACR/ARHP Annual Meeting
Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life
Jean Darloy¹, René-Marc Flipo¹, Nicolas Segaud², Jean-Paul Eschard³, Vincent Goeb⁴, Jean-Hugues Salmon³, Eric Houvenagel⁵, Clément Chopin³, Samuel Gally⁶, David Pau⁷, Isabelle Idier⁸ and Guy Baudens⁹, ¹Rheumatology, Rheumatology Department CHU Teaching Hospital Lille, Lille, France, ²Internal medicine, Internal Medicine Departement Armentières Hospital, Armentières, France, ³Rheumatology, Rheumatology Department CHU Teaching Hospital Reims, Reims, France, ⁴Rheumatologie, Rheumatology Department CHU Teaching Hospital Amiens, Amiens, France, ⁵Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁶Clinical Operations, Roche SAS, Boulogne Billancourt, France, ⁷Statistics, Roche SAS, Boulogne Billancourt, France, ⁸Medical department, Chugai Pharma France, Paris La Defense, France, ⁹Rheumatology, Rheumatology Department CHR Valenciennes, Valenciennes, France
Background/Purpose: It has been proven, in a pivotal RCT, that SC TCZ was non-inferior to IV TCZ [1]. However, the effectiveness of the SC TCZ…
Abstract Number: 525 • 2017 ACR/ARHP Annual Meeting
Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center
Richard Meehan¹, Isabelle Amigues², David Muram³, Eric Hoffman⁴, Jim Crooks⁵, Tho Truong⁶ and Pearlanne Zelarney⁷, ¹MEDICINE, National Jewish Health, Denver, CO, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Medicine/Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Rheumatology, National Jewish Health, Denver, CO, ⁷Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: The goal of therapy of rheumatoid arthritis (RA) is to achieve a state of low disease activity (LDA) or remission and reduce joint damage…
Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting
Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Shinya Kawashiri^1,2,3, Ayako Nishino^3,4, Nobutaka Eiraku³, Tamami Yoshitama³, Naoki Matsuoka³, Toshiyuki Aramaki³, Yukitaka Ueki³, Akitomo Okada³, Hiroaki Hamada³, Shuji Nagano³, Keita Fujikawa³ and Atsushi Kawakami^1,3, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁴Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…
Abstract Number: 1562 • 2017 ACR/ARHP Annual Meeting
Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Numa Simons¹, Yannick Degboé¹, Thomas Barnetche², Alain Cantagrel¹, Adeline Ruyssen-Witrand¹ and Arnaud Constantin¹, ¹Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France
Background/Purpose: We are currently witnessing a diversification of the available biotherapies (bDMARDs) for psoriatic arthritis (PsA), with the arrival of new classes of medication. Those…
Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting
Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Patricia Bogas¹, Chamaida Plasencia-Rodriguez¹, Alejandro Balsa¹, Victoria Navarro-Compán², Gema Bonilla¹, Enrique Moral Coro¹, Carolina Tornero¹, Laura Nuño¹ and Diana Peiteado³, ¹Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Arata Nakajima¹, Masato Sonobe¹, Shinji Taniguchi¹ and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ²Toho University Sakura Medical Center, Sakura-city, Chiba, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 1810 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception
Julia D Flint¹, Maria Mouyis² and Ian Giles³, ¹Medicine, University College London, London, United Kingdom, ²Rheumatology Department, Northwick Park Hospital, London, United Kingdom, ³Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom
Background/Purpose: There is limited evidence relating to the impact of disease modifying anti-rheumatic drugs (DMARDs) upon male fertility and on pregnancies conceived by men with rheumatic…
Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
B Haraoui¹, Janet E. Pope², Isabelle Fortin³, Emmanouil Rampakakis⁴, John S. Sampalis^5,6, Francoise Romeyer⁷, Joseph Atallah⁷ and Louis Bessette⁸, ¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷Bristol-Myers Squibb, Montreal, QC, Canada, ⁸Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…

« Previous Page
1
…
5
6
7
8
9
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].